Abstract
Breast cancer remains a common malignancy in women, but the take-up for breast cancer screening programs in Japan is still low, possibly due to its perceived inconvenience. TFF1 and TFF3 are expressed in both breast cancer tissue and normal breast. Serum trefoil proteins were reported as cancer screening markers for gastric, prostate, lung, pancreatic cancer and cholangio carcinoma. The purpose of this study was to examine whether serum trefoil proteins could be screening biomarkers for breast cancer. Serum trefoil proteins in 94 breast cancer patients and 84 health check females were measured by ELISA. Serum TFF1 and TFF3 were significantly higher and serum TFF2 was significantly lower in breast cancer patients. Area under the curve of receiver operating characteristic of TFF1, TFF2, and TFF3 was 0.69, 0.83, and. 0.72, respectively. AUC of the combination of TFF1, TFF2, and TFF3 was 0.96. Immunohistochemically, TFF1 expression was positive in 56.5% and TFF3 was positive in 73.9% of breast cancers, while TFF2 was negative in all tumors. Serum TFF1 had positive correlation with expression of TFF1 in breast cancer tissue. Serum concentrations of TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.
Highlights
Breast cancer remains a common malignancy in women, but the take-up for breast cancer screening programs in Japan is still low, possibly due to its perceived inconvenience
TFF1 and TFF3 are reported to be expressed in human breast epithelium in lower amounts, but there is no expression of TFF214
The expression of TFF1 and TFF3 differs between malignant cells isolated from patients with lung adenocarcinoma and those isolated from patients with breast adenocarcinoma[24]
Summary
Breast cancer remains a common malignancy in women, but the take-up for breast cancer screening programs in Japan is still low, possibly due to its perceived inconvenience. Serum trefoil proteins were reported as cancer screening markers for gastric, prostate, lung, pancreatic cancer and cholangio carcinoma. Breast cancer screening with mammography or ultrasound is provided for women beginning at 40 years of age by local governments in Japan, the response rate for the examination is only 34.2% in 20132. We have previously reported that serum TFF3 can be used as a screening marker for gastric cancer[18] It can be a biomarker for pancreatic cancer (manuscript under preparation). Detection of TFF1 and TFF3 mRNAs in peripheral blood has been proposed as a surrogate measure of circulating tumor cells[25] These findings prompted us to analyze whether serum TFF1, TFF2, and TFF3 can be biomarkers for breast cancer[18, 20, 26, 27]. We have analyzed whether serum TFF1, TFF2, and TFF3 can be biomarkers of breast cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
